🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

503 results for “Regeneron” Clear

  1. linvoseltamab

    Regeneron UK Limited

    Food Allergy

    phase 1 small molecule active

    1 trial

  2. nesvacumab (REGN910/ SAR307746)

    Regeneron UK Limited

    Solid Tumors

    phase 1 small molecule completed

    2 trials

  3. rilonacept (IL-1 Trap)

    Regeneron UK Limited

    Systemic Juvenile Idiopathic Arthritis

    phase 1 small molecule completed

    1 trial

  4. ziv-aflibercept

    Regeneron UK Limited

    Cancer

    phase 1 mab completed

    2 trials

  5. ziv-aflibercept

    Regeneron UK Limited

    Lymphoma

    phase 1 mab completed

    2 trials

  6. Aflibercept

    Regeneron UK Limited

    Submacular Vascularized Pigment Epithelial Detachments

    approved small molecule completed

    1 trial

  7. Aflibercept

    Regeneron UK Limited

    Diabetic Macular Edema

    approved small molecule completed

    2 trials

  8. Aflibercept

    Regeneron UK Limited

    Retinal Vein Occlusion

    approved small molecule active

    2 trials

  9. Aflibercept

    Regeneron UK Limited

    Fibrovascular Pigment Epithelial Detachment

    approved small molecule terminated

    1 trial

  10. Aflibercept

    Regeneron UK Limited

    Diabetic Retinopathy

    approved small molecule completed

    2 trials

  11. Aflibercept

    Regeneron UK Limited

    Age Related Macular Degeneration

    approved small molecule active

    1 trial

  12. Aflibercept

    Regeneron UK Limited

    Exudative Macular Degeneration

    approved small molecule completed

    1 trial

  13. Aflibercept (2.0 mg)

    Regeneron UK Limited

    Macular Edema With Central Retinal Vein Occlusions

    approved small molecule completed

    1 trial

  14. Aflibercept (BAY86-5321, Eylea)

    Regeneron UK Limited

    Diabetic Macular Edema

    approved small molecule completed

    1 trial

  15. Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

    Regeneron UK Limited

    Wet Macular Degeneration

    approved small molecule completed

    1 trial

  16. Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

    Regeneron UK Limited

    Neovascular Macular Degeneration

    approved small molecule completed

    1 trial

  17. Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)

    Regeneron UK Limited

    Diabetic Macular Edema (DME)

    approved small molecule active

    1 trial

  18. Aflibercept Injection

    Regeneron UK Limited

    Diabetic Retinopathy

    approved small molecule completed

    2 trials

  19. Aflibercept Ophthalmic

    Regeneron UK Limited

    Wet Macular Degeneration

    approved small molecule completed

    1 trial

  20. Alirocumab

    Regeneron UK Limited

    Atherosclerosis

    approved small molecule active

    1 trial

  21. Alirocumab

    Regeneron UK Limited

    Myocardial Infarction

    approved small molecule terminated

    2 trials

  22. Alirocumab

    Regeneron UK Limited

    Dyslipidemia

    approved small molecule completed

    1 trial

  23. Alirocumab 150 MG/ML subcutaneous injection

    Regeneron UK Limited

    Saphenous Vein Graft Atherosclerosis

    approved small molecule terminated

    1 trial

  24. Alirocumab SAR236553

    Regeneron UK Limited

    Hypercholesterolemia

    approved small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources